425 related articles for article (PubMed ID: 22288877)
21. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy.
Grober ED; Lamb DJ; Khera M; Murthy L; Lipshultz LI
Int J Impot Res; 2008; 20(6):561-5. PubMed ID: 18843272
[TBL] [Abstract][Full Text] [Related]
22. Testosterone replacement therapy can increase circulating endothelial progenitor cell number in men with late onset hypogonadism.
Liao CH; Wu YN; Lin FY; Tsai WK; Liu SP; Chiang HS
Andrology; 2013 Jul; 1(4):563-9. PubMed ID: 23653307
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study.
Wang C; Berman N; Longstreth JA; Chuapoco B; Hull L; Steiner B; Faulkner S; Dudley RE; Swerdloff RS
J Clin Endocrinol Metab; 2000 Mar; 85(3):964-9. PubMed ID: 10720024
[TBL] [Abstract][Full Text] [Related]
24. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men.
Swerdloff RS; Wang C; Cunningham G; Dobs A; Iranmanesh A; Matsumoto AM; Snyder PJ; Weber T; Longstreth J; Berman N
J Clin Endocrinol Metab; 2000 Dec; 85(12):4500-10. PubMed ID: 11134099
[TBL] [Abstract][Full Text] [Related]
25. Evidence-based medicine update on testosterone replacement therapy (TRT) in male hypogonadism: focus on new formulations.
Giagulli VA; Triggiani V; Corona G; Carbone D; Licchelli B; Tafaro E; Resta F; Sabbà C; Maggi M; Guastamacchia E
Curr Pharm Des; 2011; 17(15):1500-11. PubMed ID: 21521164
[TBL] [Abstract][Full Text] [Related]
26. A novel testosterone 2% gel for the treatment of hypogonadal males.
Dobs AS; McGettigan J; Norwood P; Howell J; Waldie E; Chen Y
J Androl; 2012; 33(4):601-7. PubMed ID: 21979302
[TBL] [Abstract][Full Text] [Related]
27. Randomized cross-over clinical trial of injectable vs. implantable depot testosterone for maintenance of testosterone replacement therapy in androgen deficient men.
Fennell C; Sartorius G; Ly LP; Turner L; Liu PY; Conway AJ; Handelsman DJ
Clin Endocrinol (Oxf); 2010 Jul; 73(1):102-9. PubMed ID: 19891698
[TBL] [Abstract][Full Text] [Related]
28. Testosterone replacement therapy for late-onset hypogonadism.
Cunningham GR
Nat Clin Pract Urol; 2006 May; 3(5):260-7. PubMed ID: 16691239
[TBL] [Abstract][Full Text] [Related]
29. [Scrotal testosterone patches: a good addition to therapeutic options for hypogonadal men].
Asscheman H; Gooren LJ
Ned Tijdschr Geneeskd; 2000 Apr; 144(18):847-50. PubMed ID: 10816775
[TBL] [Abstract][Full Text] [Related]
30. Serum testosterone levels in non-dosed females after secondary exposure to 1.62% testosterone gel: effects of clothing barrier on testosterone absorption.
Stahlman J; Britto M; Fitzpatrick S; McWhirter C; Testino SA; Brennan JJ; Zumbrunnen TL
Curr Med Res Opin; 2012 Feb; 28(2):291-301. PubMed ID: 22188558
[TBL] [Abstract][Full Text] [Related]
31. Testosterone replacement therapy: current trends and future directions.
Nieschlag E; Behre HM; Bouchard P; Corrales JJ; Jones TH; Stalla GK; Webb SM; Wu FC
Hum Reprod Update; 2004; 10(5):409-19. PubMed ID: 15297434
[TBL] [Abstract][Full Text] [Related]
32. Testosterone supplementation for hypogonadal men by the nasal route.
Mattern C; Hoffmann C; Morley JE; Badiu C
Aging Male; 2008 Dec; 11(4):171-8. PubMed ID: 19172548
[TBL] [Abstract][Full Text] [Related]
33. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
Zhang GY; Gu YQ; Wang XH; Cui YG; Bremner WJ
J Androl; 1998; 19(6):761-8. PubMed ID: 9876028
[TBL] [Abstract][Full Text] [Related]
34. One-year efficacy and safety study of a 1.62% testosterone gel in hypogonadal men: results of a 182-day open-label extension of a 6-month double-blind study.
Kaufman JM; Miller MG; Fitzpatrick S; McWhirter C; Brennan JJ
J Sex Med; 2012 Apr; 9(4):1149-61. PubMed ID: 22321357
[TBL] [Abstract][Full Text] [Related]
35. Skin reactions in a phase 3 study of a testosterone topical solution applied to the axilla in hypogonadal men.
Muram D; Melby T; Alles Kingshill E
Curr Med Res Opin; 2012 May; 28(5):761-6. PubMed ID: 22458919
[TBL] [Abstract][Full Text] [Related]
36. Testim 1% testosterone gel for the treatment of male hypogonadism.
Bouloux P
Clin Ther; 2005 Mar; 27(3):286-98. PubMed ID: 15878382
[TBL] [Abstract][Full Text] [Related]
37. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale.
Ho CC; Tong SF; Low WY; Ng CJ; Khoo EM; Lee VK; Zainuddin ZM; Tan HM
BJU Int; 2012 Jul; 110(2):260-5. PubMed ID: 22093057
[TBL] [Abstract][Full Text] [Related]
38. Transdermal delivery of testosterone.
Hadgraft J; Lane ME
Eur J Pharm Biopharm; 2015 May; 92():42-8. PubMed ID: 25709060
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic characteristics, efficacy, and safety of buccal testosterone in hypogonadal males: a pilot study.
Dobs AS; Hoover DR; Chen MC; Allen R
J Clin Endocrinol Metab; 1998 Jan; 83(1):33-9. PubMed ID: 9435413
[TBL] [Abstract][Full Text] [Related]
40. Testosterone metabolism and replacement therapy in patients with end-stage renal disease.
Johansen KL
Semin Dial; 2004; 17(3):202-8. PubMed ID: 15144546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
